Key result
Positron emission tomography (PET) imaging enables noninvasive visualization of metabolic and molecular processes in cardiovascular diseases, facilitating early detection and personalized treatment.
PET imaging provides a noninvasive, sensitive method for early detection and personalized treatment of cardiovascular diseases.
May advance PET for early CVD detection; leaves open prospective validation before clinical adoption.
Cardiovascular diseases (CVDs) are the leading cause of death worldwide and represent a great challenge for modern research and medicine. Despite advances in preventing and treating CVD over the decades, there remains an urgent need to develop sensitive and safe methods for early detection and personalized treatment. With refinements of molecular imaging technologies such as positron emission tomography (PET), noninvasive imaging of CVDs is experiencing impressive progress in both preclinical and clinical settings. In this review, we summarize advances in cardiovascular PET imaging, highlight the latest development of CVD imaging probes, and illustrate the potential for individualized therapy based on metabolic phenotype.
No takes yet. Share an insight, caveat, or question.
Li et al. (2017) conducted a review in Cardiovascular diseases. Positron emission tomography (PET) imaging was evaluated. Positron emission tomography (PET) imaging enables noninvasive visualization of metabolic and molecular processes in cardiovascular diseases, facilitating early detection and personalized treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: